“Meet-URO Score Validation in Real-World Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib: A Subanalysis of the Prospective ProPAXI Study”. Journal of Kidney Cancer 12, no. 4 (October 13, 2025): 7–18. Accessed October 20, 2025. https://mail.jkcvhl.com/~jkcvhlco/index.php/jkcvhl/article/view/403.